The UNCODE Study: Unravelling the Neural Contributors Of Dynapenia in Elders
NCT ID: NCT02505529
Last Updated: 2019-03-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
89 participants
INTERVENTIONAL
2015-07-31
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Development of Clinical Methods to Evaluate Neural Function in Aging
NCT02073201
Neural Correlates of Successful Cognitive Aging
NCT02628548
Non-expensive and Widely Available Tests as Diagnostic Tools in Dementia and Their Ability to Predict Disease Progression
NCT01642420
Indiana University Dementia Screening Trial
NCT01699503
Non-invasive, Wearable Multi-parameter System for the Early Prediction of Cognitive Decline and Dementia in Older Adults
NCT04262674
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Resistance Exercise Training
12-weeks of high-intensity, progressive resistance exercise training (3x/wk).
Resistance Exercise Training
Behavioral interventions of resistance exercise
Mental Imagery
6-weeks of mental imagery of strong muscle contractions and mobility tasks (5x/wk).
Mental Imagery
Behavioral intervention of mental imagery
Control Group
6-weeks of no change in lifestyle.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Resistance Exercise Training
Behavioral interventions of resistance exercise
Mental Imagery
Behavioral intervention of mental imagery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index between 16.0 and 40.0 kg/m2.
* With no condition that would limit participation in supervised resistance training exercise based on the Physical Activity Readiness Questionnaire (PAR-Q) (for the "Resistance Exercise Training Sub-Study only).
* Willingness to maintain current diet and adhere to the intervention programs described for the sub-studies (if applicable) and willing to undergo all testing procedures.
* Able to read, understand, and complete study-related questionnaires
* Able to read and understand, and willing to sign the informed consent form (ICF).
Exclusion Criteria
* Any activity of daily living (ADL) disability (difficulty feeding, dressing, continence, bathing, toileting, and transferring).
* Lives in a nursing home; persons living in assisted or independent housing will not be excluded.
* Cognitive impairment, defined as a known diagnosis of dementia or Modified Mini-Mental State exam score \<24
* Known neuromuscular or neurological conditions affecting somatosensory or motor function or control (e.g., hemiplegia, multiple sclerosis, peripheral neuropathy, Parkinson's disease, Myasthenia Gravis, Ataxia, Apraxia, post-polio syndrome, mitochondrial myopathy, etc.).
* Unable to communicate because of severe hearing loss or speech disorder.
* Severe visual impairment, which would preclude completion of the assessments.
* Cancer requiring treatment currently or in the past 2 years (except primary non-melanoma skin cancer or in situ cervical cancer)
* Hospitalization (medical confinement for ≥24 hours), or immobilization, or major surgical procedure requiring general anesthesia within 12 weeks prior to screening, or any planned surgical procedures during the study period.
* Chronic or relapsing/remitting gastrointestinal disorders such as inflammatory bowel disease and irritable bowel syndrome.
* Known history of human immunodeficiency virus (HIV) antibody at screening.
* Use of systemic glucocorticoids.
* Severe pulmonary disease, requiring either steroid pills or injections or the use of supplemental oxygen.
* Severe cardiac disease, including New York Heart Association (NYHA) Class III or IV congestive heart failure, clinically significant aortic stenosis, recent history of cardiac arrest (within 6-months), use of a cardiac defibrillator, or uncontrolled angina.
* Renal failure on hemodialysis
* Psychiatric conditions that warrant acute or chronic therapeutic intervention (e.g., major depressive disorder, bipolar disorder, panic disorder, schizophrenia) that in the investigators opinion may interfere with the conduct of study procedures
* Unable to undergo MRI or transcranial magnetic stimulation (TMS) (e. g. body containing any metallic medical devices or equipment, including heart pacemakers, metal prostheses, implants or surgical clips, any prior injury from shrapnel or grinding metal, exposure to metallic dusts, metallic shavings or having tattoos containing metallic dyes).
* Unable to reliably undergo exercise or strength tests described for this study.
* Participation in progressive resistance exercise within the previous 24 weeks prior to screening (for sub-studies only).
* Participation in any clinical trial within 12 weeks prior to screening (for sub-studies only).
* Limb amputation (except for toes) and/or any fracture within 24 weeks.
* Osteoarthritis, rheumatologic diseases or orthopedic disorders that will not allow completion of the motions required for the resistance exercise (for Resistance Exercise Training Sub-Study only).
* Conditions (such as myasthenia gravis, myositis, muscular dystrophy or myopathy, including drug-induced myopathy) leading to muscle loss, muscle weakness, muscle cramps or myalgia.
* Acute viral or bacterial upper or lower respiratory infection at screening
* Abnormal or uncontrolled blood pressure at the screening visit defined as diastolic BP \>100 and/or systolic BP \>170 mm Hg; if taking anti-hypertensive medication, have to be on stable doses of medication for more than 3 months.
* Medications known to alter the investigators' primary TMS-based outcomes. For instance, individuals taking benzodiazepines will be excluded from study participation.
* Current or recent history (within 1 year of screen) of heavy alcohol consumption or drug abuse that in the investigators opinion may interfere with the conduct of study procedures.
* Subjects with the following abnormal ECG findings at screening will be excluded: Electrocardiogram findings indicative of left ventricular hypertrophy (LVH) (based on Cornell voltage criteria):
* For men: S in V3 plus R in a VL \>2.8 milliVolts (mV) (28 mm)
* For women: S in V3 plus R in a VL \>2.0 mV (20 mm)
* Electrocardiogram finding of QT prolongation
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Aging (NIA)
NIH
University of Florida
OTHER
Holzer Health System
UNKNOWN
Ohio University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brian C Clark, PhD
Role: PRINCIPAL_INVESTIGATOR
Ohio University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ohio Musculoskeletal and Neurological Institute (OMNI) at Ohio University
Athens, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tavoian D, Clark BC, Clark LA, Wages NP, Russ DW. Comparison of strategies for assessment of rate of torque development in older and younger adults. Eur J Appl Physiol. 2024 Feb;124(2):551-560. doi: 10.1007/s00421-023-05299-w. Epub 2023 Aug 25.
Wages NP, Simon JE, Clark LA, Amano S, Russ DW, Manini TM, Clark BC. Relative contribution of muscle strength, lean mass, and lower extremity motor function in explaining between-person variance in mobility in older adults. BMC Geriatr. 2020 Jul 28;20(1):255. doi: 10.1186/s12877-020-01656-y.
Related Links
Access external resources that provide additional context or updates about the study.
Ohio Musculoskeletal and Neurological Institute (OMNI) Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14F038
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.